Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

By Scott M. Grundy, J. Cleeman, C. Bairey Merz, H. Brewer, Luther T. Clark, Donald B. Hunninghake, Richard C. Pasternak, Sidney C. Smith, Neil J. Stone. Arteriosclerosis, Thrombosis and Vascular Biology, 2004

1,377 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/d71e8095e44dff4adef0b5f9cc63519f9c97a39a

Citations in the corpus

• Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. (2016, neutral): “The following inclusion criteria were required to be eligible for the meta-regression analysis: (1) randomized clinical trial; (2) single intervention difference between the experimental and control group (which could either be therapy to lower LDL-C vs no therapy or, for 6 trials, more intensive vs”
• 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, neutral): “The Expert Panel acknowledges that our process did not provide for a comprehensive approach to the detection, evaluation, and treatment of lipid disorders as was done in the prior ATP III Report (6).”
• Standards of Medical Care in Diabetes—2012 (2011, neutral): “After 5.3 years of follow-up, CVD risk factors were modestly but significantly more improved with intensive treatment.”